[HTML][HTML] Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer
DVT Catenacci, MR Junttila, T Karrison… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
DVT Catenacci, MR Junttila, T Karrison, N Bahary, MN Horiba, SR Nattam, R Marsh…
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.govPurpose Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is
overexpressed in> 70% of pancreatic cancers (PCs). We investigated the impact of
vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in
a multicenter phase Ib/randomized phase II trial and preclinical PC models.
overexpressed in> 70% of pancreatic cancers (PCs). We investigated the impact of
vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in
a multicenter phase Ib/randomized phase II trial and preclinical PC models.
Abstract
Purpose
Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in> 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial and preclinical PC models.
ncbi.nlm.nih.gov
